Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 09:00 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...
September 29, 2025 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today...
September 25, 2025 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today...